Pharmacokinetics of ketoprofen in patients with chronic renal failure. 1981

G Stafanger, and H W Larsen, and H Hansen, and Sørensen

The pharmacokinetics of ketoprofen were studied in 7 volunteers and in 5 patients suffering from varying degrees of renal insufficiency. All the subjects received a single oral dose (50 mg) of ketoprofen. Plasma concentrations were measured up to 24 hours after administration and urinary excretion for 2 days. Ketoprofen concentrations were determined by mass-fragmentography with a minimum level of detection of 0.02 mg/l. As expected, a reduction of the [51Cr]EDTA clearance was correlated with an increase in the elimination half-life of ketoprofen. The urinary excretion corresponded to results reported by other groups.

UI MeSH Term Description Entries
D007660 Ketoprofen An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis. Benzoylhydratropic Acid,19,583 RP,2-(3-Benzoylphenyl)propionic Acid,Alrheumat,Alrheumum,Orudis,Profenid,RP-19583,RP 19583,RP, 19,583,RP19583
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008401 Gas Chromatography-Mass Spectrometry A microanalytical technique combining mass spectrometry and gas chromatography for the qualitative as well as quantitative determinations of compounds. Chromatography, Gas-Liquid-Mass Spectrometry,Chromatography, Gas-Mass Spectrometry,GCMS,Spectrometry, Mass-Gas Chromatography,Spectrum Analysis, Mass-Gas Chromatography,Gas-Liquid Chromatography-Mass Spectrometry,Mass Spectrometry-Gas Chromatography,Chromatography, Gas Liquid Mass Spectrometry,Chromatography, Gas Mass Spectrometry,Chromatography, Mass Spectrometry-Gas,Chromatography-Mass Spectrometry, Gas,Chromatography-Mass Spectrometry, Gas-Liquid,Gas Chromatography Mass Spectrometry,Gas Liquid Chromatography Mass Spectrometry,Mass Spectrometry Gas Chromatography,Spectrometries, Mass-Gas Chromatography,Spectrometry, Gas Chromatography-Mass,Spectrometry, Gas-Liquid Chromatography-Mass,Spectrometry, Mass Gas Chromatography,Spectrometry-Gas Chromatography, Mass,Spectrum Analysis, Mass Gas Chromatography
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010666 Phenylpropionates Derivatives of 3-phenylpropionic acid, including its salts and esters.
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes

Related Publications

G Stafanger, and H W Larsen, and H Hansen, and Sørensen
April 1987, Clinical pharmacokinetics,
G Stafanger, and H W Larsen, and H Hansen, and Sørensen
April 1984, Polskie Archiwum Medycyny Wewnetrznej,
G Stafanger, and H W Larsen, and H Hansen, and Sørensen
September 1992, Acta radiologica (Stockholm, Sweden : 1987),
G Stafanger, and H W Larsen, and H Hansen, and Sørensen
January 1983, European journal of drug metabolism and pharmacokinetics,
G Stafanger, and H W Larsen, and H Hansen, and Sørensen
April 2011, British journal of anaesthesia,
G Stafanger, and H W Larsen, and H Hansen, and Sørensen
January 1984, European journal of clinical pharmacology,
G Stafanger, and H W Larsen, and H Hansen, and Sørensen
January 1983, European journal of clinical pharmacology,
G Stafanger, and H W Larsen, and H Hansen, and Sørensen
January 1985, Clinical pharmacokinetics,
G Stafanger, and H W Larsen, and H Hansen, and Sørensen
January 1996, European journal of clinical pharmacology,
G Stafanger, and H W Larsen, and H Hansen, and Sørensen
May 2019, European review for medical and pharmacological sciences,
Copied contents to your clipboard!